🇺🇸 FDA
Pipeline program

Rituximab

2018-002882-20

Phase 3 small_molecule terminated

Quick answer

Rituximab for Kidney Transplant Rejection is a Phase 3 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Kidney Transplant Rejection
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials